Skip to main content
. 2016 Oct 1;7(47):76667–76683. doi: 10.18632/oncotarget.12395

Figure 5. miR-22 targets human MAVS.

Figure 5

(A) The predicted miR-22 target sequence in the 3′-UTR of MAVS was downloaded from TargetScan. The mutant construct that contains four base pair mutations is shown below. The upper panel is the schematic diagram showing dual-luciferase reporter constructs harboring 3′-UTR of MAVS. (B) 293T cells were co-transfected with miR-22 mimics, miR-22 inhibitors, or the corresponding control oligo (final concentration, 50 nM) together with a wild-type (Wt) or mutated (Mut) MAVS 3′- UTR dual-luciferase reporter plasmid, and Renilla luciferase activity was measured and normalized to firefly luciferase activity after 24 h. (C and D) U251 cells were transfected with miR-22 mimics, miR-22 inhibitors, or the corresponding control oligo (final concentration, 50 nM), and then MAVS mRNA (C) and protein levels (D) were determined after 48 h with quantitative real-time PCR and immunoblotting, respectively. Protein levels were quantified with immunoblot scanning and normalized to the amount of GAPDH expression. All data are representative of at least three independent experiments. (**p < 0.01; ***p < 0.001).